Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy

Ioannis A. Vathiotis, Jennifer M. Johnson, Athanassios Argiris

Research output: Contribution to journalReview articlepeer-review

Abstract

Anti-programmed cell death protein 1 immunotherapy has become the new standard in the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). However, the population that benefits is small, warranting drug combinations and novel approaches. HNSCC is a profoundly immunosuppressive disease, characterized by the interplay among different immune regulatory pathways. As clinical trials evaluating immunotherapy combinations in patients with HNSCC have started producing preliminary results, preclinical evidence on potential new targets for combination immunotherapy continues to accumulate. This review summarizes emerging clinical and preclinical data on immunotherapy combinations for the treatment of HNSCC.

Original languageEnglish (US)
Article number102192
JournalCancer Treatment Reviews
Volume97
DOIs
StatePublished - Jun 2021
Externally publishedYes

Keywords

  • HNSCC
  • Immunotherapy
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy'. Together they form a unique fingerprint.

Cite this